UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 5, 2022
CHEMBIO DIAGNOSTICS, INC.
|
Nevada
|
0-30379
|
88-0425691
|
|
(State or Other Jurisdiction of Incorporation or
Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
555 Wireless Blvd. Hauppauge, NY 11788
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (631) 924-1135
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol
|
|
Name of
each exchange on which registered
|
|
Common
Stock, $0.01 par value
|
|
CEMI
|
|
The
NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item
2.02 |
Results
of Operations and Financial Condition.
|
On May 5, 2022, we issued a press release announcing financial
results for the quarter ended March 31, 2022. The full text of the
press release is furnished as Exhibit 99.1 to this Current Report
on Form 8‑K and is incorporated herein by reference.
The information contained in this Item 2.02 and in the press
release furnished as Exhibit 99.1 to this report shall not be
deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of
Section 11 or Section 12(a)(2) of the Securities Act of 1933. The
information contained in this Item 2.02 and in the press release
furnished as Exhibit 99.1 to this report shall not be incorporated
by reference into any filing with the Securities and Exchange
Commission made by us whether made before or after the date hereof,
regardless of any general incorporation language in such
filing.
|
Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit
No.
|
|
Description
|
|
|
|
Press Release of
Chembio Diagnostics, Inc., dated May 5, 2022
|
| |
|
|
|
104
|
|
Cover Page
Interactive Data File (embedded within the Inline XBRL
document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be filed on its
behalf by the undersigned hereunto duly authorized.
|
|
Chembio Diagnostics, Inc.
|
|
|
|
|
Dated:
May 5, 2022
|
By:
|
/s/
Richard L. Eberly
|
|
|
|
Chief
Executive Officer and President
|
